These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 217022)

  • 1. Clinical and laboratory studies of live cytomegalovirus vaccine Ad-169.
    Neff BJ; Weibel RE; Buynak EB; McLean AA; Hilleman MR
    Proc Soc Exp Biol Med; 1979 Jan; 160(1):32-7. PubMed ID: 217022
    [No Abstract]   [Full Text] [Related]  

  • 2. The status of cytomegalovirus vaccine.
    Starr SE; Friedman HM; Plotkin SA
    Rev Infect Dis; 1991; 13 Suppl 11():S964-5. PubMed ID: 1664136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human cytomegalovirus vaccine: time to look for alternative options.
    Khanna R; Diamond DJ
    Trends Mol Med; 2006 Jan; 12(1):26-33. PubMed ID: 16337831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus vaccine in renal transplant candidates: progress report of a randomized, placebo-controlled, double-blind trial.
    Balfour HH; Sachs GW; Welo P; Gehrz RC; Simmons RL; Najarian JS
    Birth Defects Orig Artic Ser; 1984; 20(1):289-304. PubMed ID: 6329368
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevention of cytomegalovirus disease by Towne strain live attenuated vaccine.
    Plotkin SA; Smiley ML; Friedman HM; Starr SE; Fleisher GR; Wlodaver C; Dafoe DC; Friedman AD; Grossman RA; Barker CF
    Birth Defects Orig Artic Ser; 1984; 20(1):271-87. PubMed ID: 6329367
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytomegalovirus vaccine virus (Towne strain) does not induce latency.
    Plotkin SA; Huang ES
    J Infect Dis; 1985 Aug; 152(2):395-7. PubMed ID: 2993436
    [No Abstract]   [Full Text] [Related]  

  • 7. Progress toward developing a cytomegalovirus vaccine.
    Marshall GS; Plotkin SA
    Infect Dis Clin North Am; 1990 Jun; 4(2):283-98. PubMed ID: 2161034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus vaccine.
    Plotkin SA
    Am Heart J; 1999 Nov; 138(5 Pt 2):S484-7. PubMed ID: 10539854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge.
    Plotkin SA; Starr SE; Friedman HM; Gönczöl E; Weibel RE
    J Infect Dis; 1989 May; 159(5):860-5. PubMed ID: 2540247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines for the prevention of human cytomegalovirus infection.
    Plotkin SA; Starr SE; Friedman HM; Gonczol E; Brayman K
    Rev Infect Dis; 1990; 12 Suppl 7():S827-38. PubMed ID: 2173112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial.
    Plotkin SA; Starr SE; Friedman HM; Brayman K; Harris S; Jackson S; Tustin NB; Grossman R; Dafoe D; Barker C
    Ann Intern Med; 1991 Apr; 114(7):525-31. PubMed ID: 1848053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination against cytomegalovirus, the changeling demon.
    Plotkin SA
    Pediatr Infect Dis J; 1999 Apr; 18(4):313-25; quiz 326. PubMed ID: 10223683
    [No Abstract]   [Full Text] [Related]  

  • 13. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.
    Pass RF; Duliegè AM; Boppana S; Sekulovich R; Percell S; Britt W; Burke RL
    J Infect Dis; 1999 Oct; 180(4):970-5. PubMed ID: 10479120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Could a vaccine against immune-evading cytomegalovirus become a reality?
    Emery VC
    Expert Rev Vaccines; 2011 Aug; 10(8):1109-11. PubMed ID: 21854303
    [No Abstract]   [Full Text] [Related]  

  • 15. Encouraging prospects for immunisation against primary cytomegalovirus infection.
    Griffiths PD; McLean A; Emery VC
    Vaccine; 2001 Jan; 19(11-12):1356-62. PubMed ID: 11163656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Live cytomegalovirus vaccination of healthy volunteers: eight-year follow-up studies.
    Stern H
    Birth Defects Orig Artic Ser; 1984; 20(1):263-9. PubMed ID: 6329366
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial: Congenital cytomegalovirus infection--more problems.
    Lancet; 1974 May; 1(7862):845-6. PubMed ID: 4132794
    [No Abstract]   [Full Text] [Related]  

  • 18. Prospects for the clinical management of human cytomegalovirus infections.
    Farrar GH; Bull JR; Greenaway PJ
    Vaccine; 1986 Dec; 4(4):217-24. PubMed ID: 3026105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).
    Adler SP; Plotkin SA; Gonczol E; Cadoz M; Meric C; Wang JB; Dellamonica P; Best AM; Zahradnik J; Pincus S; Berencsi K; Cox WI; Gyulai Z
    J Infect Dis; 1999 Sep; 180(3):843-6. PubMed ID: 10438376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA vaccines against cytomegalovirus: current progress.
    Temperton NJ
    Int J Antimicrob Agents; 2002 Mar; 19(3):169-72. PubMed ID: 11932137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.